These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6642131)

  • 21. The usual dose of I-13U used to ablate thyroid.
    Caplan RH; Dvorak D
    J Nucl Med; 1977 Sep; 18(9):946. PubMed ID: 893800
    [No Abstract]   [Full Text] [Related]  

  • 22. Improved planning of radioiodine therapy for thyroid cancer.
    Medvedec M
    J Nucl Med; 2002 May; 43(5):714; author reply 714. PubMed ID: 11994536
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
    Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma.
    Hermanská J; Kárný M; Zimák J; Jirsa L; Sámal M; Vlcek P
    J Nucl Med; 2001 Jul; 42(7):1084-90. PubMed ID: 11438632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring.
    Bal C; Kumar A; Tripathi M; Chandrashekar N; Phom H; Murali NR; Chandra P; Pant GS
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):449-55. PubMed ID: 16095849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Online regulatory guide errors.
    Dawry FP
    J Nucl Med; 2002 Feb; 43(2):284. PubMed ID: 11858234
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
    Brierley J; Tsang R; Panzarella T; Bana N
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):418-27. PubMed ID: 16181234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy of thyroid cancer.
    Duthie MB
    Br J Radiol; 1971 Oct; 44(526):819. PubMed ID: 5117061
    [No Abstract]   [Full Text] [Related]  

  • 29. [131I-therapy of hyperthyroidism--10 years' follow-up study].
    Tsuchigame T; Yasunaga T; Hirota Y; Yano K; Ueno S; Bussaka H; Takahashi M; Yoshii H; Fukui K; Nakamura I; Kaneko T
    Rinsho Hoshasen; 1983 May; 28(5):589-93. PubMed ID: 6887615
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radioiodine therapy in differentiated thyroid gland carcinoma].
    Schicha H; Dietlein M
    Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine therapy in differentiated thyroid carcinoma.
    Salvatori M; Rufini V; Garganese MC; Di Giuda D
    Rays; 2000; 25(2):221-38. PubMed ID: 11370540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of thyroid cancer with 131I-results on 72 cases (author's transl)].
    Oyamada H; Terui S; Ebihara S; Ono I; Saito H
    Horumon To Rinsho; 1981 Apr; 29(4):405-11. PubMed ID: 7296911
    [No Abstract]   [Full Text] [Related]  

  • 35. [Radiometabolic therapy in differentiated carcinoma of the thyroid gland].
    Casara D
    Chir Ital; 1994; 46(4):53-5. PubMed ID: 7882444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
    J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.
    M'Kacher R; Légal JD; Schlumberger M; Aubert B; Beron-Gaillard N; Gaussen A; Parmentier C
    J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The real cost of theoretic risk avoidance: the need to challenge unsubstantiated concerns about (131)I therapy.
    Goldsmith SJ
    J Nucl Med; 2011 May; 52(5):681-2. PubMed ID: 21498535
    [No Abstract]   [Full Text] [Related]  

  • 40. [Nuclear medicine--therapeutic advances into new dimensions?].
    Hahn K
    Rofo; 2000 Mar; 172(3):207-9. PubMed ID: 10778449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.